Novavax Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 60.93. In total, the insiders bought 2 085 166 and sold 490 065 NVAX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
60.93
Buy 2 085 166 Shares
Sell 490 065 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 21, 2024 Common Stock Sell Young James F 7 500
Jun 18, 2024 Common Stock Sell Young James F 6 393
Jun 18, 2024 Common Stock Sell Young James F 1 107
Jun 17, 2024 Common Stock Buy Dubovsky Filip 12 500
Jun 17, 2024 Common Stock Buy Dubovsky Filip 1 404
Jun 17, 2024 Common Stock Sell Dubovsky Filip 12 500
Jun 17, 2024 Common Stock Sell Dubovsky Filip 1 404
Jun 17, 2024 Stock Option (Right to Buy) Sell Dubovsky Filip 1 404
Jun 17, 2024 Stock Option (Right to Buy) Sell Dubovsky Filip 12 500
Jun 12, 2024 Stock Option (Right to Buy) Buy Mcglynn Margaret G 15 630
Jun 12, 2024 Common Stock Buy Mcglynn Margaret G 6 670
Jun 12, 2024 Restricted Stock Units Buy Mcglynn Margaret G 10 420
Jun 12, 2024 Restricted Stock Units Sell Mcglynn Margaret G 6 670
Jun 12, 2024 Stock Option (Right to Buy) Buy Alton Gregg H 15 630
Jun 12, 2024 Common Stock Buy Alton Gregg H 6 670
Jun 12, 2024 Restricted Stock Units Buy Alton Gregg H 10 420
Jun 12, 2024 Restricted Stock Units Sell Alton Gregg H 6 670
Jun 12, 2024 Common Stock Buy Douglas Richard 6 670
Jun 12, 2024 Stock Option (Right to Buy) Buy Douglas Richard 15 630
Jun 12, 2024 Restricted Stock Units Buy Douglas Richard 10 420
Jun 12, 2024 Restricted Stock Units Sell Douglas Richard 6 670
Jun 12, 2024 Common Stock Buy King Rachel K. 6 670
Jun 12, 2024 Stock Option (Right to Buy) Buy King Rachel K. 15 630
Jun 12, 2024 Restricted Stock Units Buy King Rachel K. 10 420
Jun 12, 2024 Restricted Stock Units Sell King Rachel K. 6 670
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT